A share price of Fulcrum Therapeutics Inc [FULC] is currently trading at $6.90, up 8.66%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FULC shares have gain 5.99% over the last week, with a monthly amount glided 93.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fulcrum Therapeutics Inc [NASDAQ: FULC] stock has seen the most recent analyst activity on May 23, 2025, when Leerink Partners upgraded its rating to a Outperform but kept the price target unchanged to $12 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on May 15, 2025, and kept the price target unchanged to $10. On September 13, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Stifel downgraded its rating to a Hold. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $4 on September 12, 2024. Leerink Partners downgraded its rating to Market Perform for this stock on September 12, 2024, but kept the price target unchanged to $4. In a note dated September 12, 2024, Cantor Fitzgerald downgraded an Neutral rating on this stock.
Fulcrum Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.32 and $10.13. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $6.90 at the most recent close of the market. An investor can expect a potential return of 73.91% based on the average FULC price forecast.
Analyzing the FULC fundamentals
Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.16%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.42 points at the first support level, and at 5.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.19, and for the 2nd resistance point, it is at 7.48.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Fulcrum Therapeutics Inc [NASDAQ:FULC] is 28.71. In addition, the Quick Ratio stands at 28.71 and the Cash Ratio stands at 5.21. Considering the valuation of this stock, the price to sales ratio is 4.66, the price to book ratio is 1.63.
Transactions by insiders
Recent insider trading involved Tourangeau Greg, Principal Accounting Officer, that happened on May 08 ’25 when 498.0 shares were sold.
